Literature DB >> 32909650

Four-Year Follow-up of [18 F]Fluorodeoxyglucose Positron Emission Tomography-Based Parkinson's Disease-Related Pattern Expression in 20 Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder Shows Prodromal Progression.

Rosalie V Kogan1, Annette Janzen2, Sanne K Meles3, Elisabeth Sittig2, Remco J Renken4, Vita Gurvits1, Geert Mayer2, Klaus L Leenders1,3, Wolfgang H Oertel2,5.   

Abstract

BACKGROUND: Isolated rapid eye movement sleep behavior disorder is known to be prodromal for alpha-synucleinopathies, such as Parkinson's disease (PD) and dementia with Lewy bodies. The [18 F]fluorodeoxyglucose-positron emission tomography (PET)-based PD-related brain pattern can be used to monitor disease progression.
OBJECTIVE: We longitudinally investigated PD-related brain pattern expression changes in 20 subjects with isolated rapid eye movement sleep behavior disorder to investigate whether this may be a suitable technique to study prodromal PD progression in these patients and to identify potential phenoconverters.
METHODS: Subjects underwent two [18 F]fluorodeoxyglucose-PET brain scans ~3.7 years apart, along with baseline and repeated motor, cognitive, and olfactory testing within roughly the same time frame.
RESULTS: At baseline, 8 of 20 (40%) subjects significantly expressed the PD-related brain pattern (with z scores above the receiver operating characteristic-determined threshold). At follow-up, six additional subjects exhibited significant PD-related brain pattern expression (70% in total). PD-related brain pattern expression increased in all subjects (P = 0.00008). Four subjects (20%), all with significant baseline PD-related brain pattern expression, phenoconverted to clinical PD.
CONCLUSIONS: Suprathreshold PD-related brain pattern expression and greater score rate of change may signify greater shorter-term risk for phenoconversion. Our results support the use of serial PD-related brain pattern expression measurements as a prodromal PD progression biomarker in patients with isolated rapid eye movement sleep behavior disorder.
© 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease-related pattern; [18F]FDG-PET; neuroimaging; prodromal progression biomarker; rapid eye movement sleep behavior disorder

Mesh:

Year:  2020        PMID: 32909650      PMCID: PMC7891341          DOI: 10.1002/mds.28260

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  25 in total

1.  Abnormal metabolic network activity in REM sleep behavior disorder.

Authors:  Florian Holtbernd; Jean-François Gagnon; Ron B Postuma; Yilong Ma; Chris C Tang; Andrew Feigin; Vijay Dhawan; Mélanie Vendette; Jean-Paul Soucy; David Eidelberg; Jacques Montplaisir
Journal:  Neurology       Date:  2014-01-22       Impact factor: 9.910

2.  A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia.

Authors:  Pasquale Anthony Della Rosa; Chiara Cerami; Francesca Gallivanone; Annapaola Prestia; Anna Caroli; Isabella Castiglioni; Maria Carla Gilardi; Giovanni Frisoni; Karl Friston; John Ashburner; Daniela Perani
Journal:  Neuroinformatics       Date:  2014-10

3.  Identification of disease-related spatial covariance patterns using neuroimaging data.

Authors:  Phoebe Spetsieris; Yilong Ma; Shichun Peng; Ji Hyun Ko; Vijay Dhawan; Chris C Tang; David Eidelberg
Journal:  J Vis Exp       Date:  2013-06-26       Impact factor: 1.355

4.  Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease.

Authors:  Chris C Tang; Kathleen L Poston; Vijay Dhawan; David Eidelberg
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

5.  Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series.

Authors:  Carlos H Schenck; Bradley F Boeve; Mark W Mahowald
Journal:  Sleep Med       Date:  2013-01-22       Impact factor: 3.492

6.  The clinically important difference on the unified Parkinson's disease rating scale.

Authors:  Lisa M Shulman; Ann L Gruber-Baldini; Karen E Anderson; Paul S Fishman; Stephen G Reich; William J Weiner
Journal:  Arch Neurol       Date:  2010-01

7.  Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.

Authors:  Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle
Journal:  Mov Disord       Date:  2008-11-15       Impact factor: 10.338

Review 8.  Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.

Authors:  Ian G McKeith; Bradley F Boeve; Dennis W Dickson; Glenda Halliday; John-Paul Taylor; Daniel Weintraub; Dag Aarsland; James Galvin; Johannes Attems; Clive G Ballard; Ashley Bayston; Thomas G Beach; Frédéric Blanc; Nicolaas Bohnen; Laura Bonanni; Jose Bras; Patrik Brundin; David Burn; Alice Chen-Plotkin; John E Duda; Omar El-Agnaf; Howard Feldman; Tanis J Ferman; Dominic Ffytche; Hiroshige Fujishiro; Douglas Galasko; Jennifer G Goldman; Stephen N Gomperts; Neill R Graff-Radford; Lawrence S Honig; Alex Iranzo; Kejal Kantarci; Daniel Kaufer; Walter Kukull; Virginia M Y Lee; James B Leverenz; Simon Lewis; Carol Lippa; Angela Lunde; Mario Masellis; Eliezer Masliah; Pamela McLean; Brit Mollenhauer; Thomas J Montine; Emilio Moreno; Etsuro Mori; Melissa Murray; John T O'Brien; Sotoshi Orimo; Ronald B Postuma; Shankar Ramaswamy; Owen A Ross; David P Salmon; Andrew Singleton; Angela Taylor; Alan Thomas; Pietro Tiraboschi; Jon B Toledo; John Q Trojanowski; Debby Tsuang; Zuzana Walker; Masahito Yamada; Kenji Kosaka
Journal:  Neurology       Date:  2017-06-07       Impact factor: 9.910

9.  FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder.

Authors:  Sanne K Meles; David Vadasz; Remco J Renken; Elisabeth Sittig-Wiegand; Geert Mayer; Candan Depboylu; Kathrin Reetz; Sebastiaan Overeem; Angelique Pijpers; Fransje E Reesink; Teus van Laar; Lisette Heinen; Laura K Teune; Helmut Höffken; Marcus Luster; Karl Kesper; Sofie M Adriaanse; Jan Booij; Klaus L Leenders; Wolfgang H Oertel
Journal:  Mov Disord       Date:  2017-07-22       Impact factor: 10.338

10.  Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients.

Authors:  Alex Iranzo; Ana Fernández-Arcos; Eduard Tolosa; Mónica Serradell; José Luis Molinuevo; Francesc Valldeoriola; Ellen Gelpi; Isabel Vilaseca; Raquel Sánchez-Valle; Albert Lladó; Carles Gaig; Joan Santamaría
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

View more
  7 in total

1.  Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder.

Authors:  Annette Janzen; David Vadasz; Jan Booij; Markus Luster; Damiano Librizzi; Martin T Henrich; Lars Timmermann; Mahboubeh Habibi; Elisabeth Sittig; Geert Mayer; Fanni Geibl; Wolfgang Oertel
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

2.  Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease.

Authors:  Jan Rusz; Jan Hlavnička; Michal Novotný; Tereza Tykalová; Amelie Pelletier; Jacques Montplaisir; Jean-Francois Gagnon; Petr Dušek; Andrea Galbiati; Sara Marelli; Paul C Timm; Luke N Teigen; Annette Janzen; Mahboubeh Habibi; Ambra Stefani; Evi Holzknecht; Klaus Seppi; Elisa Evangelista; Anna Laura Rassu; Yves Dauvilliers; Birgit Högl; Wolfgang Oertel; Erik K St Louis; Luigi Ferini-Strambi; Evžen Růžička; Ronald B Postuma; Karel Šonka
Journal:  Ann Neurol       Date:  2021-05-07       Impact factor: 10.422

3.  Efficacy of 11C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane positron emission tomography combined with 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of early Parkinson disease: A protocol for systematic review and meta analysis.

Authors:  Lei Jiang; Xixian Wang; Pengtao Li; Zhaohai Feng; Xin Shi; Hua Shao
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

Review 4.  Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease.

Authors:  Sanne K Meles; Wolfgang H Oertel; Klaus L Leenders
Journal:  Mol Med       Date:  2021-09-16       Impact factor: 6.354

Review 5.  Prodromal Cognitive Deficits and the Risk of Subsequent Parkinson's Disease.

Authors:  Daniël H B Speelberg; Jules M Janssen Daalen; Bastiaan R Bloem; Jean-François Gagnon; Bart Post; Sirwan K L Darweesh
Journal:  Brain Sci       Date:  2022-01-31

Review 6.  Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder.

Authors:  Mitchell G Miglis; Charles H Adler; Elena Antelmi; Dario Arnaldi; Luca Baldelli; Bradley F Boeve; Matteo Cesari; Irene Dall'Antonia; Nico J Diederich; Kathrin Doppler; Petr Dušek; Raffaele Ferri; Jean-François Gagnon; Ziv Gan-Or; Wiebke Hermann; Birgit Högl; Michele T Hu; Alex Iranzo; Annette Janzen; Anastasia Kuzkina; Jee-Young Lee; Klaus L Leenders; Simon J G Lewis; Claudio Liguori; Jun Liu; Christine Lo; Kaylena A Ehgoetz Martens; Jiri Nepozitek; Giuseppe Plazzi; Federica Provini; Monica Puligheddu; Michal Rolinski; Jan Rusz; Ambra Stefani; Rebekah L S Summers; Dallah Yoo; Jennifer Zitser; Wolfgang H Oertel
Journal:  Lancet Neurol       Date:  2021-08       Impact factor: 44.182

Review 7.  Predictors of RBD progression and conversion to synucleinopathies.

Authors:  Edoardo Rosario de Natale; Heather Wilson; Marios Politis
Journal:  Curr Neurol Neurosci Rep       Date:  2022-03-11       Impact factor: 5.081

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.